You are here

Press Releases

Exsurco® Medical, Inc. announces the launch of a new wound debridement and skin grafting medical device designed for use in burn and trauma centers. Backed by Exsurco’ s knowledge and ground breaking design and innovation, the new Amalgatome® SD is a revolutionary break-through in combining skin grafting and wound debridement technology in an industry that hasn’t seen this kind of innovation for a multiple use device. By using one device for multiple procedures (excision and/or auto grafting), the Amalgatome SD helps those who are in critical need of the healing power of skin.

G4S has launched an innovative portable security system to monitor the safety of vulnerable patients.

ImagineSoftware today announced it has entered into a strategic agreement with Merge, an IBM company. ImagineSoftware will assume frontline support for Merge Financials and Merge Sentinel customers, and will provide an option for those customers to upgrade to Imagine's innovative platform for medical billing automation.

The growing demand for quality healthcare has revolutionised the health monitoring space through use of wearable and ingestible sensors. Emphasis on preventive health has lead to the development of prognostic sensors for applications in medical space. This has lead to the shift of healthcare business model from a diagnostic one to more prognostic and preventive health and wellness. Sensor adoption is crucial to this evolution, facilitating advanced diagnostics, treatment, and patient monitoring. Wearable and implantable biosensors will emerge as the key enablers for device innovation, as well as will be commercialised as prognostic tools.

DePuy Synthes Products, Inc., part of the Johnson & Johnson Family of Companies, has acquired 3D printing technology from Tissue Regeneration Systems, Inc. (TRS). The 3D printing methods developed by TRS will help enable DePuy Synthes to create patient-specific, bioresorbable implants with a unique mineral coating intended to support bone healing in patients with orthopaedic and craniomaxillofacial deformities and injuries. Financial terms of the transaction have not been disclosed.

electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement, announced today that the U.S. Food and Drug Administration (FDA) released the use of gammaCore® (non-invasive vagus nerve stimulator) for the acute treatment of pain associated with episodic cluster headache in adult patients. gammaCore transmits a mild electrical stimulation to the vagus nerve through the skin, resulting in a reduction of pain. This is the first FDA product release for electroCore in the U.S.

Records Bank, a division of HemCare Health Services Inc. (OTC: HCRE) is pleased to announce the launch of its Free Medical Record Storage and Transfer program for health care providers.

Spok, Inc., a wholly owned subsidiary of Spok Holdings, Inc. (NASDAQ: SPOK) and the global leader in healthcare communications, today released the first of two reports on the results of the annual mobility strategies in healthcare survey. This research, conducted by Spok since 2011, is designed to assess mobile workflow enablement progress and trends in hospitals across the country.

The IDBS E-WorkBook Cloud has been shortlisted for Cloud Product of the Year

Company to Develop and Commercialize Precision Photomedicine Devices

Lower penile bulb radiation dose may be associated with ability to maintain sexual function and potency

Siemens Healthineers establishes digital platform for healthcare providers as well as for providers of solutions and services

JPI Healthcare announces that we are now representing the Carestream Health product line. JPI is pleased to be able to provide a greater range of Digital Solutions to our growing dealer network.

Memorial Healthcare System in Hollywood, Fla., purchased the Digisonics HL7 Discrete Data Export interface.

Solution Enables Long-Term and Post-Acute Care Providers to Achieve Higher Ratings

ONE YEAR AFTER IMPLANT, 93 PERCENT OF PATIENTS WHO CONTINUED SCS THERAPY HAD LOWER AVERAGE DAILY MORPHINE-EQUIVALENT DOSES THAN PATIENTS WHO HAD THEIR SCS SYSTEM REMOVED

Researchers at Mayo Clinic have identified a genetic promoter of cancer that drives a major form of lung cancer.

Company Develops Innovative New Technologies for Medical, Healthcare IT and Dental Imaging Systems

Infusion System Exchanges Data with Leading EMR and Alarm Management Systems to Improve Patient Safety, Care Quality and Outcomes

Another Suspension of Disruptive Tax Won’t Have Same Economic Impact

Pages